Price alert —
Sign in to get a one-time email the moment TEVA crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · TEVA
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.0B | $0.4B | $0.8B | $-0.2B | 9.3% | 19.1% |
| 2025-12-31 | $4.7B | $0.5B | $1.3B | $1.0B | 10.2% | 26.9% |
| 2025-09-30 | $4.5B | $0.4B | $1.1B | $0.2B | 9.7% | 24.0% |
| 2025-06-30 | $4.2B | $0.3B | $0.9B | $0.1B | 6.8% | 21.5% |
| 2025-03-31 | $3.9B | $0.2B | $0.7B | $-0.2B | 5.5% | 18.1% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare TEVA vs peers
Line TEVA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with TEVA
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-29 | 0.53 | 0.46 | +16.2% | -0.9% |
| 2026-01-28 | 0.96 | 0.64 | +50.2% | -0.4% |
| 2025-11-05 | 0.78 | 0.67 | +15.7% | -0.6% |
| 2025-07-30 | 0.66 | 0.62 | +7.3% | -8.2% |
| 2025-05-07 | 0.52 | 0.46 | +12.2% | +2.7% |
| 2025-01-29 | 0.71 | 0.70 | +1.1% | -3.8% |
| 2024-11-06 | 0.69 | 0.66 | +4.4% | +0.4% |
| 2024-07-31 | 0.61 | 0.55 | +10.7% | +0.6% |
| 2024-05-08 | 0.48 | 0.51 | -6.7% | +1.6% |
| 2024-01-31 | 1.00 | 0.76 | +31.7% | +3.0% |
| 2023-11-08 | 0.60 | 0.61 | -1.9% | -4.2% |
| 2023-08-02 | 0.56 | 0.53 | +6.1% | +3.5% |
| 2023-05-10 | 0.40 | 0.55 | -27.9% | -1.7% |
| 2023-02-08 | 0.71 | 0.71 | -0.6% | -1.0% |
| 2022-11-03 | 0.59 | 0.62 | -4.2% | -1.6% |
| 2022-07-26 | 0.68 | 0.56 | +20.6% | +28.4% |
| 2022-05-03 | 0.55 | 0.55 | +0.2% | -3.1% |
| 2022-02-09 | 0.77 | 0.73 | +6.0% | -2.0% |
| 2021-10-27 | 0.59 | 0.65 | -8.6% | -2.2% |
| 2021-07-28 | 0.59 | 0.59 | -0.5% | -3.0% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| TEVA ★ | $37B | 23.9 | 10.4 | 2.1 | 10.1 | 4.5 | 52.1% | 2.3% | 72.2% | 7.00% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 33.42%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 65,136,464 | 5.59% |
| Harel Insurance Investments & Financ | 45,956,714 | 3.95% |
| Phoenix Financial Ltd. | 42,777,414 | 3.67% |
| WCM Investment Management, LLC | 40,820,600 | 3.51% |
| Menora Mivtachim Holdings Ltd. | 39,626,383 | 3.40% |
| Clal Insurance Enterprises Holdings | 38,446,506 | 3.30% |
| Migdal Insurance & Financial Holding | 37,902,212 | 3.25% |
| FMR, LLC | 33,132,795 | 2.84% |
| Lingotto Investment Management LLP | 27,770,857 | 2.38% |
| State Street Corporation | 17,790,020 | 1.53% |
Insider activity · 90d
0 buys / 3 sells · ratio 0.0 · Finnhub
- Shields Matthew SELL 0 @ $32.19
- Kalif Eliyahu Sharon SELL 65,621 @ $34.10
- Lichtenstein Chen M 0
- Lichtenstein Chen M 19,296
- Satchi-Fainaro Ronit M 0
- Satchi-Fainaro Ronit M 112,401
- Elstein Amir M 0
- Elstein Amir M 2,118,455
- Zaks Tal Zvi M 0
- Zaks Tal Zvi M 73,264
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-22 | 4 | view · |
| 4 | 2026-06-16 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-08 | 4 | view · |
| 4 | 2026-06-04 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 4 | 2026-06-01 | 4 | view · |
| 8-K | 2026-05-28 | 8-K | view · |
| 4 | 2026-05-18 | 4 | view · |
| 4 | 2026-05-18 | 4 | view · |
| 4 | 2026-05-07 | 4 | view · |
| 4 | 2026-05-07 | 4 | view · |
| 4 | 2026-05-04 | 4 | view · |
| 4 | 2026-05-04 | 4 | view · |
| 10-Q | 2026-04-29 | 10-Q | view · |
| 8-K | 2026-04-29 | FORM 8-K | view · |
| DEF 14A | 2026-03-31 | DEF 14A | view · |
| 4 | 2026-03-19 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-09 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-06 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
| 4 | 2026-03-05 | 4 | view · |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesi…
Options picks · TEVA
ITM + OTM ideas from the latest scanLoading…
Congress trades · TEVA
STOCK Act disclosuresLoading…
SEC filings & insiders · TEVA
EDGAR · liveLoading…
Holders · TEVA
Institutions & insider activityLoading…